Home > Boards > US Listed > Biotechs > Chimerix, Inc. (CMRX)

Chimerix to present Phase 1 data for CMX521

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
H8ster Member Profile
 
Followed By 82
Posts 5,933
Boards Moderated 1
Alias Born 01/23/10
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2020 4:07:28 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 9/30/2020 9:57:20 AM
Chimerix to Participate in Upcoming Investor Conferences GlobeNewswire Inc. - 9/10/2020 8:00:10 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 8/21/2020 4:31:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/19/2020 5:35:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/11/2020 5:50:45 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 8/11/2020 8:20:53 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/10/2020 5:54:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 4:39:59 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/10/2020 7:18:40 AM
Chimerix Reports Second Quarter 2020 Financial Results and Provides Operational Update GlobeNewswire Inc. - 8/10/2020 7:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/6/2020 12:55:52 PM
Chimerix to Report Second Quarter 2020 Financial Results and Provide an Operational Update on August 10, 2020 GlobeNewswire Inc. - 8/3/2020 8:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/23/2020 1:02:59 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 6/23/2020 1:00:23 PM
Chimerix Appoints Allen Melemed, M.D. as Chief Medical Officer GlobeNewswire Inc. - 6/22/2020 7:00:10 AM
Chimerix to Present at H.C. Wainwright Virtual Fireside Chat Series GlobeNewswire Inc. - 6/18/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/15/2020 1:18:33 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2020 12:49:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2020 12:45:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2020 12:44:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2020 12:43:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2020 12:41:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2020 12:41:22 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2020 12:39:27 PM
H8ster   Friday, 06/08/18 05:45:53 PM
Re: None
Post # of 625 
Chimerix to present Phase 1 data for CMX521 at the 31st annual ISAR, The International Conference on Antiviral Research June 11th-June 15th 2018.

Q1 CC

"Details of the discovery and preclinical development of CMX521 will be presented next month at the International Conference on Antiviral Research. Our ongoing Phase 1 studies are designed to evaluate the pharmacokinetics, safety and tolerability of this novel nucleoside. Data from Phase 1 will allow us to choose optimize dosing regimens to take into Phase 2 efficacy studies in 2019."

"In late 2017, we initiated our first time in human study of CMX521, a nucleoside analog identified from our chemical library as a potential treatment and/or prevention for norovirus. We see this as a great commercial opportunity, as there are currently no approved therapies for the treatment of chronic norovirus infection or for use as a prevention strategy to limit the spread of an outbreak."………….

"Norovirus represents a large and costly unmet need. Each year, there are over 700 million cases resulting in 219,000 deaths. There’s also a significant economic toll, as the cost associated with norovirus is over $60 billion a year. And it’s not just a cruise ship virus, as it frequently impacts long-term care facilities and hospitals, causing ward shutdowns and infections among patients and health care providers.

Approaching the different prevention market segments will include looking at a number of important variables depending upon the setting. For example, in a norovirus outbreak, where there’s central area of control, such as in military facilities, hospitals or medical care settings, a protocol for use can be put in place to quickly disseminate an antiviral for preventing the further spread of this highly contagious virus.

We’ve already done exploratory market research with long-term care facilities, who are very interested in the CMX521 product profile, indicating that the product could have utility not only for preventing infection in patients, but also protecting staff."



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences